Sterilization, Packaging and Shelf Life Validation for Sterile Devices in Belarus
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The registration evidence for a sterile device is a chain: the sterilization method is defined, sterilization is validated, packaging is validated, shelf life is validated, and the expiry date declared on the label closes the loop. If any link in this chain is missing or inconsistent with the others, the entire sterility claim fails to stand, however strong the remaining links may be.
The practical consequence for planning is that sterile products carry a longer evidence runway than non-sterile ones: validation work must be sequenced so that sterilization, packaging and aging studies finish in an order that allows the label to be fixed last, once the data are known. Inverting that order, by printing labels before the aging data exist, is the classic way to create the mismatches described below.
2. Legal basis
| Regulation | Number or identifier | Date of publication or entry into force | Key provisions |
|---|---|---|---|
| Decision of the Council of the Eurasian Economic Commission on General Safety and Effectiveness Requirements, Labeling and Operating Documentation | No. 27 | 2016-02-12 | Safety and effectiveness requirements and labeling requirements |
| On Preliminary Technical Work Prior to State Registration | Ministry of Health No. 55 (amended by No. 120) | 2015-04-23 | Registration dossier document requirements |
| On State Registration (Re-registration) of Medical Devices | Council of Ministers No. 211 (6-1/55925) | Effective 2026-05-01 | Registration procedure; closed list principle |
| Technical regulation of Belarus, Medical Devices. Safety | TR 2010/006/BY | Current | National safety requirements |
3. Expert insights
Insight one: sterilization validation must answer whether the required sterility level can be achieved reliably. The core of the validation is to demonstrate that under the established sterilization parameters the product consistently reaches the required sterility assurance level, and that the parameters remain effective for the product load and packaging configuration in question. The load configuration, the selection of worst-case conditions, and the placement of biological indicators in the validation report are the points on which reviewers concentrate their attention first.
Insight two: packaging validation is the link most often omitted. Sterility is maintained by the packaging, so the seal integrity, the compatibility with the sterilization method, and the integrity after transport all need validation. Performing sterilization validation without packaging validation leaves the sterility claim logically incomplete, and reviewers are entitled to reject the file on that ground alone, because a sterile claim that cannot survive handling is not a claim at all.
Insight three: the shelf life must cover the label declaration. The period supported by the shelf life validation, whether by real-time aging or by accelerated aging confirmed with real-time data, must be no shorter than the expiry date stated on the label. A mismatch between the two is a common reason for requests for correction, and it is also one of the easiest mismatches to avoid, since it requires only a careful comparison before submission.
Insight four: the closed list principle matters here as well. Since No. 211 prohibits expanding the preliminary technical work list, an enterprise may ask for the legal basis when asked to add validation items beyond that list. Note, however, that what is closed is the list of items, not the depth of work: the methodological depth required for items already on the list still has to be satisfied in full.
Insight five: the chain logic also disciplines how the assembled file is read. A reviewer who opens the sterilization section will next look for the packaging section that preserves the validated state, then for the shelf life section that certifies how long the state is preserved, and finally for the label that states the result. Each transition between sections is a place where data can contradict data. Reading the dossier along this chain before submission, in the same order a reviewer would, is the most economical way to find the inconsistencies while they are still free to fix.
4. Practical recommendations
- Self-check item by item along the chain. Confirm all four elements, sterilization validation, packaging validation, shelf life validation and the label expiry declaration, and check that the data are consistent across them.
- Align the validation conditions with the label declaration. The storage conditions and expiry date on the label must correspond one to one with the validated conditions.
- Plan real-time aging early. Real-time aging takes a long time; if the target shelf life is long, start it early in the registration preparation so that it does not become the bottleneck for obtaining the certificate.
- Keep the worst-case justification on record. The validation protocol should state in writing why the chosen load and conditions represent the worst case.
5. Verification checklist
- □ Sterilization validation, packaging validation, shelf life validation and the label declaration are all complete
- □ Validation conditions are aligned with the labeled storage conditions and expiry date
- □ Real-time aging has been started early and its required stages completed
- □ The selection of worst-case conditions is justified in writing
- □ Requests to add validation items beyond the list have been checked against the principle of No. 211
Regulatory information verified as of October 30, 2026.
In the Eurasian Economic Union market, the core capabilities of GRZAN concentrate on three points. First, distinguishing between the two channels of Union-wide registration and national registration in each member state, including their applicable conditions and remaining time windows. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of April 28, 2026 (state register number 6-1/55925, effective May 1, 2026), which compressed the total time limit for preliminary technical work to 90 calendar days, applied a closed list that the implementing organization is prohibited from expanding, while applications under the national procedure face the key deadline of December 31, 2027, so pathway selection must be decided in sync with the time window. Second, local authorized representative services, acting as the legal representative of the manufacturer in Belarus, handling registration submission, responses to technical queries, changes to the registration dossier, and post-market reporting obligations; GRZAN has updated its coordination mechanisms after Council of Ministers Resolution No. 378 of July 27, 2026 (effective July 30, 2026) transferred adverse event functions to the state institution Gosfarmnadzor. Third, quality system and testing support, assisting in establishing a quality management system compliant with ISO 13485 and organizing the technical documentation according to the target pathway: for the national pathway, the annex to Ministry of Health Resolution No. 55; for the Union pathway, Decision No. 46 of the Council of the Eurasian Economic Commission.
Business inquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us